Paramount BioSciences, LLC (“Paramount”) is a major pharmaceutical drug development and investment organization having their principal concentration on the medical and life sciences industries. By using Paramount BioCapital, Inc., a FINRA listed broker-dealer in charge of funding and raising capital for Portfolio businesses, Paramount BioSciences greatly plays a role in the emergence and progression of modern biotechnologies and life sciences.
Paramount Biosciences’’ Brand
Not only will Paramount BioSciences furnish specialized solutions and assistance, but is additionally involved in new product enhancement, Biotech Corporation’s acquisition and development. It facilitates the freshly generated organizations in several value-adding ways. They evaluate product prospects for the Portfolio businesses; generate development strategies to facilitate the creation procedure ahead of, in the course of, as well as after the formation of Portfolio Firms. Both, back up and experience is entirely supported by BioSciences as it enables its Portfolio Firms to gain access to far more knowledgeable infrastructure than some might have. This allows the company operations to pay attention to the drug candidates’ growth instead of developing their unique infrastructure. In many ways, this kind of model produced by Paramount’s founder Lindsay Rosenwald offers both expert and “back office” help and limits delays inside the development process, in addition to maximized the profits for Portfolio firms and the patient group.
After approval and in-licensing, a role-specific administration team throughout the full creation period maintains pharmaceutical candidates. Senior pharmaceutical progression personnel at Paramount BioSciences, which include Lindsay Rosenwald, help Portfolio Firms in all of the aspects of pharmaceutical creation. This includes formulation, clinical growth, toxicology, developing, monitoring quality, and marketing. With their substantial practical experience in establishing top drug solutions, the Paramount’s group delivers options for a variety of therapeutically signs, beginning with inflammation to cardiovascular to oncology to neurology and lots of other indications. Global system of professionals as well as business market leaders in the health-related and technological fields provides assistance through the candidates’ development and acceptance period.
Having a proven track record, Paramount BioSciences facilitates Portfolio Firms hire executives that will steer the fresh businesses made throughout the new compounds. Among the current hires at Portfolio Firms, there are such executives as the former CEOs of Roche, Biogen, Johnson&Johnson, Amgen and many more.
Over two decades of financing and development of biomedical companies around a broad range of therapeutic indications, Lindsay Rosenwald is head of Paramount BioSciences’ more than 40 biotech corporations. He forms companies from the scratch employing his very own capital after which funds are raised from different private individuals through Paramount Capital.
Paramount deals with critical capabilities as accounting, legal, market analytical, monetary capabilities. This allows its Portfolio firms to give attention to scientific experiments and generating value for shareholders, licensors and patients.
With this kind of experience for locating and creating modern medications, Paramount BioSciences evaluates the quality and promises of drug candidates across the world, from little biotech companies and educational centers to large prescription firms.
Paramount Procedure To Value Creation
Exactly what tends to make Paramount BioSciences stand out, is the fact that their infrastructure and outer network permits them to assistance Paramount Incubated Organizations until finally they come to be self-sufficient. The creation routine has been designed by Lindsay Rosenwald in 1998 and may be explained in a straightforward layout similar to this one:
Product Resources –> Paramount Original Financing and Expansion –> Incubation –> Portfolio Company Formation –> Cost Inflection Level
Employees for each Portfolio Company are chosen in compliance with developmental and monetary situations. Normally, most employees at Paramount have a minimum of 12-15 years of practical experience in biotechnology or health care industries maneuvering pharmaceutical applicants throughout the regulatory and clinical value string. Their expertise ranges from molecular biology to clinical medical science.
With this kind of serious knowledge throughout the pharmaceutical creation business, Lindsay Rosenwald has managed to form the group with leadership roles in the biotech market with numerous pharmaceutical products for sale globally, including Viracept, Neulasta, Rituxan, and Kepivance.
Paramount Business Units
Paramount Biosciences
With over forty staff in eight offices globally, Paramount BioSciences contend and bargain for college and business biotechnology entitlements. It develops and in-licenses compounds for numerous restorative indications – from inflammation and cardiology to neurology and cancer. Lindsay Rosenwald may help create standalone biotech firms that will get capital and triumph as public organizations
Paramount BioCapital, Inc.
Paramount BioCapital Inc. is a NASD-registered dealer that collects cash for the Portfolio Businesses. It brought in above $1 billion and around $200 million in 2009. Making use of their extensive know-how in investments purchases such as “PIPE’s”, reverse mergers, self-registrations and private positions, Paramount BioCapital is becoming the leader within the biotechnology capital market.
Paramount Corporate and business Advancement
Lindsay Rosenwald functions directly with Paramount Corporate Development, which is involved with in-licensing and pharmaceutical development functions. The Corporate Development team comprises of 20 trade veterans with a huge experience in most facets of pharmaceutical drug development, including formulation, clinical procedures, manufacturing and commercialization.
Paramount BioCapital Property Management
Property Management is in charge of buying and disbursing equities of worldwide healthcare organizations. They have a successful hedge fund structure and property under management in numerous private placement vehicles.
Paramount Acquisition Company
Paramount Acquisition Company produces distinctive private equity finance vehicles that match up substantial capitals with late-stage private companies. It just lately announced a $54 million purchase with Valeritas, which is a medical device business with its primary FDA-approved insulin pump h-Patch.
Paramount BioSciences Professional Leadership Staff
Typically, Paramount BioSciences personnel have 15 years of primary knowledge in the specialized medical and regulatory processes. Headed by Lindsay Rosenwald, the team members participated in lots of prescription creation and commercialization jobs, including Rituxan, Viracept, Sutent, Kepivance, and Neulasta. More than fifty substances currently go through clinical advancement procedure and the products consist of drug treatments throughout a broad range of indications that include neurological ailments, metabolic conditions, transmittable conditions and cancer.
Lindsay A. Rosenwald, M.D., is CEO and Chairman at Paramount BioSciences. His considerable expertise within biotechnology, pharmacology and finance made him one of the frontrunners in the biotechnology and life sciences sectors. With more than 19 years of practical experience in building and investing in biotechnology and life science organizations, Dr. Lindsay Rosenwald set up and nurtured more than 40 biotech/pharma organizations.
J. Jay Lobell, J.D., is President and Chief Operating Officer at Paramount BioSciences. His previous experience includes partnership at Covington & Burling, where he furnished economic, regulatory, business, and litigation suggestions to financial institutions, corporations and individuals.
Russell Ellison, m.d. is Executive Vice President with more than 31 years of senior management experience in pharmaceutical drug development and commercialization he is a previous vice president clinical development at fibrogen, inc. and chief medical officer of sanofi-synthelabo, usa. Dr. Ellison also served as the U.S. vice president of medical affairs and is a former U.S. vice president, medical affairs and chief medical officer of Hoffman la roche.
Benefits of Paramount BioSciences Style
Exactly what makes Paramount BioSciences a preferred acquirer of drugs and developer of biotechnologies is that Lindsay Rosenwald’s development team along a world-wide business development group that assesses and allows for unit and market opportunities. The offices of Paramount BioSciences can be found throughout the world, which includes New York City, London, Boston, Shanghai, San Diego, North Carolina, Orange County (California)). Promising medication candidates are shifted ahead quickly in the certification process. Representatives of all areas in drug creation cycle come together to make sure an understanding to move ahead. The next thing is the creation of product development ideas for the compound and getting supervision personnel. During this period, the chemical substances are usually transferred to Portfolio Businesses with no transition hold-up. The product candidates are backed throughout the specialized medical and regulatory system.
Paramount BioSciences has proved to rapidly perform deals and initiate creation work. Its access to money is a valuable part of any product creation. It supplies Portfolio businesses with the structure that promotes drug candidate’s progression through to market, removing chances of program getting stalled.
Medical and commercial knowledge at the company level helps Paramount Portfolio firms take full advantage of value to in-licensed items.
Background regarding Financial Wherewithal
Paramount BioSciences underneath the authority of Lindsay Rosenwald has produced over $1 billion from outside shareholders in addition to their own investment in Paramount’s portfolio businesses. All firms and clinical studies funded through the company receive substantial financing on all levels of the development circuit.
Linsay Rosenwald has frequent and close interaction with the leading US sell-side and buy-side organizations that include notable medical care individuals, with whom Paramount’s hedge funds invest in the offers not directly involving the organization by itself. Paramount’s employees have real-time understanding of health care capital markets, which led to over $400 million funds for Portfolio Corporations in 2009 year alone, including $200 million by Paramount. This includes $47 million for Cougar Biosciences in partnership with SG Cowen, $37 million for Ziopharm Oncology, $22 MM for Chelsea Therapeutics and $16 million for Innovive Pharmaceuticals. Most of the leading health care funds invested in Paramount this year, which remains a good indication for the introduction of biotechnology and life sciences sectors.